Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its novel antibody-drug conjugate $(ADC)$, BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.